- Public Health - Essential Generic Drugs - Price Gouging - Prohibition
- Sponsored by
- The President (By Request - Office of the Attorney General) and Senators Conway, Astle, Benson, Currie, Feldman, Ferguson, Guzzone, Kelley, Lee, Madaleno, Manno, Mathias, McFadden, Muse, Nathan-Pulliam, Peters, Pinsky, Ramirez, Robinson, Rosapepe, Smith, Young, and Zucker
- In the Senate - Hearing 2/15 at 1:00 p.m.
- Fiscal and Policy Note
Prohibiting a manufacturer or wholesale distributor from engaging in price gouging in the sale of an essential generic drug; requiring the Maryland Medical Assistance Program to notify the manufacturer of an essential generic drug and the Attorney General of a specified increase in the price of the essential generic drug under specified circumstances; requiring a manufacturer of an essential generic drug to submit a specified statement to the Attorney General within 20 days after receipt of a specified notice; etc.
Bill File Type: Regular
Effective Date(s): October 1, 2017
( 2-801 through 2-803 )
Last Updated: 2/3/2020 2:34 PM